# BONDIR Study: A Study of Intravenous Bonviva (Ibandronate) After Recent Vertebral Osteoporotic Fracture in Patients With Osteoporosis.

> **NCT00493623** · PHASE3 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 68 (actual)

## Conditions studied

- Osteoporosis

## Interventions

- **DRUG:** Placebo
- **DRUG:** ibandronate [Bonviva/Boniva]

## Key facts

- **NCT ID:** NCT00493623
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-06
- **Primary completion:** 2009-12
- **Final completion:** 2009-12
- **Target enrollment:** 68 (ACTUAL)
- **Last updated:** 2016-03-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00493623

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00493623, "BONDIR Study: A Study of Intravenous Bonviva (Ibandronate) After Recent Vertebral Osteoporotic Fracture in Patients With Osteoporosis.". Retrieved via AI Analytics 2026-08-13 from https://api.ai-analytics.org/clinical/NCT00493623. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*